- Home
- CPRX
as 11-15-2024 4:00pm EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 2.8B | IPO Year: | 2006 |
| Target Price: | $30.50 | AVG Volume (30 days): | 984.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.18 | EPS Growth: | 114.68 |
| 52 Week Low/High: | $13.00 - $24.27 | Next Earning Date: | 11-06-2024 |
| Revenue: | $460,482,000 | Revenue Growth: | 32.17% |
| Revenue Growth (this year): | 21.99% | Revenue Growth (next year): | 17.95% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tierney David S | CPRX | Director | Aug 21 '24 | Sell | $20.10 | 15,000 | $301,455.00 | 348,874 | |
| Miller Steve | CPRX | Chief Op. & Scientific Officer | Aug 20 '24 | Sell | $20.35 | 150,000 | $3,052,900.00 | 775,124 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
Zacks
9 hours ago
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
GlobeNewswire
2 days ago
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
Simply Wall St.
3 days ago
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point
Argus Research
3 days ago
CPRX: Raising target price to $24.00
Investor's Business Daily
4 days ago
Vericel Stock Sees RS Rating Shoot Higher
GuruFocus.com
5 days ago
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Simply Wall St.
7 days ago
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
Zacks
8 days ago
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
Compare CPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.